The SURPASS trial results

Trial series summary and independent commentary provided by John Wilding, University of Liverpool. 

The dual GIP and GLP-1 receptor agonist tirzepatide has “potent glucose-lowering effects towards near-normal ranges,” and also induces significant weight loss in people with type 2 diabetes, say the SURPASS-1 investigators.
 

Researcher commentary provided by Juan Pablo Frías, National Research Institute, Los Angeles, USA

People with type 2 diabetes on metformin monotherapy have greater glycemic control improvement and weight reduction with tirzepatide than semaglutide, report the SURPASS-2 investigators.
 

Researcher commentary provided by Francesco Giorgino, University of Bari Aldo Moro, Italy.

The SURPASS-3 findings show that people with type 2 diabetes can obtain better glycemic control with tirzepatide than insulin degludec, while losing rather than gaining weight.
 

Tirzepatide provides better glucose control than insulin glargine in people with type 2 diabetes taking multiple oral antidiabetes medications, report the SURPASS-4 investigators in The Lancet. 
 

Researcher commentary provided by Michelle Welch, Diabetes and Metabolism Specialists, San Antonio, Texas, USA.

People with insulin-dependent type 2 diabetes significantly improve their glycemic control, lose weight, and require less insulin if they also have a weekly injection of tirzepatide, show the SURPASS-5 findings.